Please assess the completion status of the following clinical trial:

Trial Title: Anidulafungin in Patients With Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (≥ 18 years) with a hematologic disorder AND an indication for IFI prophylaxis or therapy, but a relative contraindication for azoles or polyenes due to hepatic or renal dysfunction\*, are scheduled to receive anidulafungin for one of the following specific indications:~* Need for primary antifungal prophylaxis in patients with Acute leucaemia/MDS during induction, reinduction or consolidation chemotherapy (who are expected to become neutropenic for at least 10 days) OR after allogenic HSCT with GvHD (at least grade II or more - systemic steroid treatment required)~* Need for secondary antifungal prophylaxis in patients with the history of a proven or probable invasive fungal infection who are expected to become neutropenic during induction, reinduction or consolidation chemotherapy~* Indication for treatment of proven\*\*, probable or possible fungal infection:~  * Neutropenic patients with fever resistant to antibiotics (empirical use)~ * Neutropenic patients with fever resistant to antibiotics and additive laboratory or imaging signs of IFI (preemptive use)~ * Patients who failed other antifungal therapy due to intolerance or progressive infection~Exclusion Criteria:~* Absence of written informed consent~* Female patients who are pregnant or lactating~* Use of anidulafungin within 30 days prior to study~* Known hypersensitivity to anidulafungin~* Proven IFI with pathogen of known resistance to echinocandins (e.g. zygomycetes)~* Life expectancy less than 1 month~* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anidulafungin, safety, antifungal drug (Type: OTHER): single arm study

Based on this trial design, predict the completion outcome and termination type (if applicable).